Alzheimer’s Disease Neuroimaging Initiative
The Division of Neuroscience, NIA sponsored this informational meeting to convene experts on neuroimaging in Alzheimer’s disease and mild cognitive impairment (MCI). Attendees represented academia, pharmaceutical companies, imaging companies, NIH program staff, the NIH Office of the Director, the Food and Drug Association, the Alzheimer’s Association, and the Institute for the Study of Aging. Approximately 38 people attended.
The goal of this initiative is to develop longitudinal studies that will identify the neuroimaging modalities and techniques that are most appropriate for following elderly people as they develop MCI and Alzheimer's disease. In addition to providing natural history information, the hope is that neuroimaging markers will allow early identification of those who may benefit from emerging preventative and treatment medications. During this initial meeting, representatives from pharmaceutical companies, imaging companies, and advocacy organizations expressed their levels of interest and concerns about participating in this initiative. NIH staff discussed the conduct of a similar initiative—osteoarthritis—which is sponsored by the National Institute of Arthritis and Musculoskeletal and Skin Diseases and NIA.
Topics discussed at this meeting included:
- Standardization of imaging protocols and data analysis
- Advantages and disadvantages of different imaging modalities
- Investigators’ experience with longitudinal imaging studies
- Criteria for surrogate markers for drug efficacy
- Data sharing
The next meeting for this initiative was planned for June 17–18, 2002.
Drs. John Hsiao and Neil Buckholtz